BioPorto A/S
THOXF
Get informed when a big investor buys or sells
+ FollowMarket Cap$529.75M
Close$
$-0.15
197.8% downside
Current Fair Value
197.8% downsideOvervalued by 197.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $529.75 Million |
|---|---|
| Enterprise Value | $460.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.15 |
| Beta | 1.38 |
| Outstanding Shares | 495,109,000 |
Return
| Return on Equity | 10.41% |
|---|---|
| Return on Assets | 7.85% |
| Return on Invested Capital | 6.77% |
Valuation & Multiples
| P/E Ratio | 80.45 |
|---|---|
| PEG | -26.98 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 12.42 |
| Enterprise Value to EBIT | 80.26 |
| Enterprise Value to Net Income | 53 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.13 M
Average shareholder expectationNext Earnings Call
Expected Date
November 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.45 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioPorto A/S
44 employees
CEO: Carsten Buhl BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offe...